VIDEO: Turing Pharmaceuticals CEO Martin Shkreli: 5,000 Percent Price Boost ‘Not Excessive at All’
In case you hadn’t heard, last month, Turing Pharmaceuticals chief executive and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 a pill. Now he has a big public relations problem and self-created health care crisis on his hands. (Heck, he may even have the makings of a rap sheet.)
Shkreli has trotted out a number of tactics in response to the firestorm directed at him since news of the price hike broke. He’s gotten into ill-advised Twitter wars. He’s tried to reframe the astronomical boost in the cost of Daraprim as the product of philanthropy instead of the profit drive.
Watch as Shkreli tries, and fails, to cure the ensuing global epidemic of Daraprim sticker shock in an interview with CBS News:
–Posted by Kasia AndersonWait, before you go…
If you're reading this, you probably already know that non-profit, independent journalism is under threat worldwide. Independent news sites are overshadowed by larger heavily funded mainstream media that inundate us with hype and noise that barely scratch the surface. We believe that our readers deserve to know the full story. Truthdig writers bravely dig beneath the headlines to give you thought-provoking, investigative reporting and analysis that tells you what’s really happening and who’s rolling up their sleeves to do something about it.
Like you, we believe a well-informed public that doesn’t have blind faith in the status quo can help change the world. Your contribution of as little as $5 monthly or $35 annually will make you a groundbreaking member and lays the foundation of our work.Support Truthdig